Drug Trial Radar · NCT00003728
Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
Last checked: Nov 20, 2026Latest source record: Jan 21, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,500
Planned (sponsor's estimate)
Start
Dec 1998
Primary completion
May 2008
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy plus steroid therapy is more effective for acute lymphoblastic leukemia or lymphoblastic non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy plus steroid therapy in treating children who have acute lymphoblastic leukemia or lymphoblastic non-Hodgkin's lymphoma.
Conditions
- Leukemia
- Lymphoma
Interventions
asparaginaseDrug
cyclophosphamideDrug
cytarabineDrug
daunorubicin hydrochlorideDrug
dexamethasoneDrug
doxorubicin hydrochlorideDrug
etoposideDrug
leucovorin calciumDrug
mercaptopurineDrug
methotrexateDrug
methylprednisoloneDrug
mitoxantrone hydrochlorideDrug
prednisoloneDrug
therapeutic hydrocortisoneDrug
thioguanineDrug
vincristine sulfateDrug
vindesineDrug
allogeneic bone marrow transplantationProcedure
peripheral blood stem cell transplantationProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival after first randomization
- Disease-free survival after second and third randomization
Locations
23 sites in 3 countries. Site status is shown where the registry gives one.
Ziekenhuis Netwerk Antwerpen Middelheim
Antwerp, Belgium
Hopital Universitaire Des Enfants Reine Fabiola
Brussels, Belgium
Academisch Ziekenhuis der Vrije Universiteit Brussel
Brussels, Belgium
Ghent University
Ghent, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
U.Z. Gasthuisberg
Leuven, Belgium
Centre Hospitalier Regional de la Citadelle
Liège, Belgium
Clinique de l'Esperance
Montegnée, Belgium
Centre Hospitalier Regional et Universitaire d'Angers
Angers, France
CHR de Besancon - Hopital Saint-Jacques
Besançon, France
CHU de Caen
Caen, France
CHU de Grenoble - Hopital de la Tronche
Grenoble, France
Hopital Debrousse
Lyon, France
Hopital Arnaud de Villeneuve
Montpellier, France
CHR Hotel Dieu
Nantes, France
Hopital de l'Archet CHU de Nice
Nice, France
CHU - Hopital Robert Debre
Paris, France
Hopital Jean Bernard
Poitiers, France
Hopital Americain
Reims, France
Hopital Universitaire Hautepierre
Strasbourg, France
Hopital des Enfants
Toulouse, France
Hospital Escolar San Joao
Porto, Portugal
Instituto Portugues de Oncologia Centro do Porto, SA
Porto, Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.